Tags

Type your tag names separated by a space and hit enter

Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
Eur J Neurol. 2018 04; 25(4):680-686.EJ

Abstract

BACKGROUND AND PURPOSE

The aim was to investigate the diagnostic utility of signal intensity measurement of the substantia nigra pars compacta (SNc) using three-dimensional (3D) neuromelanin-sensitive magnetic resonance imaging (MRI), for discrimination of patients with Parkinson's disease (PD) from healthy controls.

METHODS

T1-weighted neuromelanin-sensitive images of 16 patients with PD and 15 controls were quantitatively analyzed by placing circular 10 mm2 regions of interest over the central and lateral parts of the bilateral SNc and anterior to the cerebral aqueduct at three levels of the midbrain. Signal intensities and contrast ratios (CRs) were calculated, after which significant differences, correlations, sensitivity and specificity were calculated.

RESULTS

The CRs of the central and lateral SNc were significantly lower in patients with PD. Lateral CRs were lower than the central CRs in both groups and significantly correlated with duration of illness. CRs of central and lateral parts of the SNc also correlated with the Unified Parkinson's Disease Rating Scale III OFF state scores. Receiver operating characteristic analysis revealed lateral CRs to be more sensitive and central CRs to be more specific for the discrimination of patients with PD from controls.

CONCLUSIONS

Contrast ratio analysis of the SNc using 3D neuromelanin-sensitive MRI may serve as a quick and accurate tool to discern between patients with PD and healthy controls.

Authors+Show Affiliations

Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29341412

Citation

Prasad, S, et al. "Three-dimensional Neuromelanin-sensitive Magnetic Resonance Imaging of the Substantia Nigra in Parkinson's Disease." European Journal of Neurology, vol. 25, no. 4, 2018, pp. 680-686.
Prasad S, Stezin A, Lenka A, et al. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Eur J Neurol. 2018;25(4):680-686.
Prasad, S., Stezin, A., Lenka, A., George, L., Saini, J., Yadav, R., & Pal, P. K. (2018). Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. European Journal of Neurology, 25(4), 680-686. https://doi.org/10.1111/ene.13573
Prasad S, et al. Three-dimensional Neuromelanin-sensitive Magnetic Resonance Imaging of the Substantia Nigra in Parkinson's Disease. Eur J Neurol. 2018;25(4):680-686. PubMed PMID: 29341412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. AU - Prasad,S, AU - Stezin,A, AU - Lenka,A, AU - George,L, AU - Saini,J, AU - Yadav,R, AU - Pal,P K, Y1 - 2018/02/08/ PY - 2017/07/15/received PY - 2018/01/11/accepted PY - 2018/1/18/pubmed PY - 2019/2/5/medline PY - 2018/1/18/entrez KW - Parkinson's disease KW - contrast ratio KW - neuromelanin KW - signal intensity KW - substantia nigra SP - 680 EP - 686 JF - European journal of neurology JO - Eur J Neurol VL - 25 IS - 4 N2 - BACKGROUND AND PURPOSE: The aim was to investigate the diagnostic utility of signal intensity measurement of the substantia nigra pars compacta (SNc) using three-dimensional (3D) neuromelanin-sensitive magnetic resonance imaging (MRI), for discrimination of patients with Parkinson's disease (PD) from healthy controls. METHODS: T1-weighted neuromelanin-sensitive images of 16 patients with PD and 15 controls were quantitatively analyzed by placing circular 10 mm2 regions of interest over the central and lateral parts of the bilateral SNc and anterior to the cerebral aqueduct at three levels of the midbrain. Signal intensities and contrast ratios (CRs) were calculated, after which significant differences, correlations, sensitivity and specificity were calculated. RESULTS: The CRs of the central and lateral SNc were significantly lower in patients with PD. Lateral CRs were lower than the central CRs in both groups and significantly correlated with duration of illness. CRs of central and lateral parts of the SNc also correlated with the Unified Parkinson's Disease Rating Scale III OFF state scores. Receiver operating characteristic analysis revealed lateral CRs to be more sensitive and central CRs to be more specific for the discrimination of patients with PD from controls. CONCLUSIONS: Contrast ratio analysis of the SNc using 3D neuromelanin-sensitive MRI may serve as a quick and accurate tool to discern between patients with PD and healthy controls. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/29341412/Three_dimensional_neuromelanin_sensitive_magnetic_resonance_imaging_of_the_substantia_nigra_in_Parkinson's_disease_ L2 - https://doi.org/10.1111/ene.13573 DB - PRIME DP - Unbound Medicine ER -